PuSH - Publikationsserver des Helmholtz Zentrums München

Epstein-Barr virus reprograms human B lymphocytes immediately in the prelatent phase of infection.

Proc. Natl. Acad. Sci. U.S.A. 116, 16046-16055 (2019)
Verlagsversion DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
Epstein-Barr virus (EBV) is a human tumor virus and a model of herpesviral latency. The virus efficiently infects resting human B lymphocytes and induces their continuous proliferation in vitro, which mimics certain aspects of EBV's oncogenic potential in vivo. How lymphoblastoid cell lines (LCLs) evolve from the infected lymphocytes is uncertain. We conducted a systematic time-resolved longitudinal study of cellular functions and transcriptional profiles of newly infected naive primary B lymphocytes. EBV reprograms the cells comprehensively and globally. Rapid and extensive transcriptional changes occur within 24 h and precede any metabolic and phenotypic changes. Within 72 h, the virus activates the cells, changes their phenotypes with respect to cell size, RNA, and protein content, and induces metabolic pathways to cope with the increased demand for energy, supporting an efficient cell cycle entry on day 3 postinfection. The transcriptional program that EBV initiates consists of 3 waves of clearly discernable clusters of cellular genes that peak on day 2, 3, or 4 and regulate RNA synthesis, metabolic pathways, and cell division, respectively. Upon onset of cell doublings on day 4, the cellular transcriptome appears to be completely reprogrammed to support the proliferating cells, but 3 additional clusters of EBV-regulated genes fine-tune cell signaling, migration, and immune response pathways, eventually. Our study reveals that more than 11,000 genes are regulated upon EBV infection as naive B cells exit quiescence to enter a germinal center-like differentiation program, which culminates in immortalized, proliferating cells that partially resemble plasmablasts and early plasma cells.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
9.580
2.539
41
84
Tags
statConAck
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Epstein-barr Virus ; Reprogramming ; B Cell ; B Lymphocyte; Membrane-protein 2a; Gene-expression; Myc; Cells; Metabolism; Activation; Oncogene; Latency; Bzlf1; Old
Sprache englisch
Veröffentlichungsjahr 2019
HGF-Berichtsjahr 2019
ISSN (print) / ISBN 0027-8424
e-ISSN 1091-6490
Quellenangaben Band: 116, Heft: 32, Seiten: 16046-16055 Artikelnummer: , Supplement: ,
Verlag National Academy of Sciences
Verlagsort 2101 Constitution Ave Nw, Washington, Dc 20418 Usa
Begutachtungsstatus Peer reviewed
POF Topic(s) 30203 - Molecular Targets and Therapies
30204 - Cell Programming and Repair
30205 - Bioengineering and Digital Health
30501 - Systemic Analysis of Genetic and Environmental Factors that Impact Health
Forschungsfeld(er) Immune Response and Infection
Stem Cell and Neuroscience
Enabling and Novel Technologies
Helmholtz Diabetes Center
Genetics and Epidemiology
PSP-Element(e) G-501500-001
G-506290-001
G-503800-001
G-502800-001
G-500700-001
Scopus ID 85070187472
PubMed ID 31341086
Erfassungsdatum 2019-08-07